SCHEMBL6743012

SCHEMBL6743012

CSC(=N)N.Nc1cncc(C(=O)O)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.71
ALDH1A1 P00352 5/20 0.71
MEN1 O00255 2/20 0.71
KMT2A Q03164 2/20 0.71
LMNA P02545 1/20 0.71
DDO Q99489 1/20 0.71
HCAR2 Q8TDS4 6/20 0.47
POLB P06746 1/20 0.43
MKNK1 Q9BUB5 2/20 0.43
MKNK2 Q9HBH9 2/20 0.43
CYP2C19 P33261 2/20 0.41
CYP2C9 P11712 1/20 0.41
RAF1 P04049 1/20 0.38
MAPK1 P28482 1/20 0.35
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
CYP2D6 P10635 1/20 0.34
BLM P54132 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL185913 0.84 ALDH1A1 (1.00) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL29954828 0.84 ALDH1A1 (1.00) KDM4EALDH1A1MEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL9448329 0.82 ALDH1A1 (0.96) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL30033490 0.73 KDM4E (0.69) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL520949 0.73 KDM4E (0.69) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL4035571 0.72 CYP2C9 (0.79) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL3044926 0.71 KDM4E (0.67) KDM4EALDH1A1MEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL9448500 0.71 KDM4E (0.67) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL27750302 0.70 KDM4E (0.72) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL8325878 0.70 ALDH1A1 (0.58) KDM4EALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127477-A1 Heterocyclic glycyl beta-alanine derivatives G. D. SEARLE & CO. (US) 2004-07-01 US disclosed
US-6689754-B1 PIPERIDINE OR PYRIDINE DERIVATIVES; ALPHA V BETA 3 INTEGRIN ANTAGONISTS G. D. SEARLE & CO. 2004-02-10 US disclosed
CN-1304406-A Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists SEARLE & CO (US) 2001-07-18 CN disclosed
EP-1070060-A1 HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS G.D. Searle & Co. (US) 2001-01-24 EP disclosed
WO-1999052896-A1 HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS G.D. SEARLE & CO. (US) 1999-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127477-A1 Heterocyclic glycyl beta-alanine derivatives ITGB3, ITGAL, ITGB1 KDM4E 4376/4885ALDH1A1 388/4885MEN1 1710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.